In addition, some alkaloids can affect cholesterol and lipid metabolism in tumor cells
Clinical trial results Clinical trials have shown significant weight loss and A1C improvements
There is currently no official regulatory guidance from the MHRA, NICE, or EMA specifically addressing retatrutide, as the drug has not yet received marketing authorisation in the United Kingdom or European Union
Secondary endpoints also showed significant improvements with semaglutide
Patients experiencing changes in sexual health or serious side effects (severe abdominal pain, signs of pancreatitis or gallbladder disease) should consult their GP promptly
GLP-1-based treatments are administered subcutaneously and work by supporting your body's natural processes for appetite suppression and slowing gastric emptying, which may contribute to a feeling of fullness